InvestorsHub Logo
Followers 33
Posts 2845
Boards Moderated 1
Alias Born 10/24/2015

Re: None

Monday, 08/28/2023 6:03:02 PM

Monday, August 28, 2023 6:03:02 PM

Post# of 550
INNOVATE-3 fails. According to its final data analysis, the patients treated with TTFields plus paclitaxel had a mOS of 12.2 months compared to 11.9 months mOS in the paclitaxel-only arm https://www.businesswire.com/news/home/20230828160039/en/Novocure-Provides-Update-on-Phase-3-ENGOT-ov50-GOG-3029-INNOVATE-3-Trial-Evaluating-Tumor-Treating-Fields-Therapy-in-Platinum-resistant-Ovarian-Cancer/
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent NVCR News